Cargando…

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma

Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zundler, Sebastian, Vitali, Francesco, Kharboutli, Soraya, Völkl, Simon, Polifka, Iris, Mackensen, Andreas, Atreya, Raja, Neurath, Markus F., Mougiakakos, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240064/ https://www.ncbi.nlm.nih.gov/pubmed/37284193 http://dx.doi.org/10.3389/fonc.2023.1149450

Ejemplares similares

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
por: Baur, Rebecca, et al.
Publicado: (2021)

Role of CAR T Cell Metabolism for Therapeutic Efficacy
por: Rial Saborido, Judit, et al.
Publicado: (2022)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
por: Rath, Timo, et al.
Publicado: (2023)

Linking Immunoevasion and Metabolic Reprogramming in B-Cell–Derived Lymphomas
por: Böttcher, Martin, et al.
Publicado: (2020)

Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer
por: Zundler, Sebastian, et al.
Publicado: (2016)

Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy
por: Reimann, Hannah, et al.
Publicado: (2022)

Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
por: Wiendl, Maximilian, et al.
Publicado: (2021)

The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome
por: Richter, Silja, et al.
Publicado: (2022)

Baseline levels of dynamic CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
por: Allner, Clarissa, et al.
Publicado: (2020)

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023)

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players
por: Sommer, Katrin, et al.
Publicado: (2021)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity
por: Haug, Tabea, et al.
Publicado: (2019)

Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease
por: Lang-Schwarz, Corinna, et al.
Publicado: (2021)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9(high) AML cell subset
por: Böttcher, Martin, et al.
Publicado: (2022)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

The Oncometabolite 5′-Deoxy-5′-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation
por: Jacobs, Benedikt, et al.
Publicado: (2020)

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
por: Bücklein, V., et al.
Publicado: (2022)

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
por: Bücklein, Veit, et al.
Publicado: (2023)

T-Cell Metabolism in Graft Versus Host Disease
por: Karl, Franziska, et al.
Publicado: (2021)

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
por: Becker, Emily, et al.
Publicado: (2022)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease
por: Klenske, Entcho, et al.
Publicado: (2019)

IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner
por: Loschinski, Romy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hje66ja2k93j51u4sr4g7oefen